Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein Pharmacokinetics.

In the FcRn KO mice, chronic dosing of TfRMAb-EPO showed a trend toward a decrease in tissue levels in the kidney, spleen, and brain by 83.5% ( p = 0.93), 95.2% ( p = 0.92), and 99.7% ( p = 0.43), respectively, compared with FcRn KO mice that received a single dose of TfRMAb-EPO ( Figure 2 A,C,D).

also in 53,322 other papers